Folate-conjugated liposomes target and deliver therapeutics to immune cells in a rat model of rheumatoid arthritis
Abstract
Aim: We endeavored to create a folate-targeted liposome (Fol-liposome) that could selectively target areas of inflammation. Materials & methods: Fol-liposomes were prepared with encapsulated DiD fluorophore or betamethasone (BM) to image and treat an adjuvant-induced rat model of rheumatoid arthritis. Results: Fol-liposomes selectively accumulated in arthritic rat paws to a greater extent than nontargeted liposomes. When these Fol-liposomes were used to encapsulate BM and administered to arthritic rats, animals exhibited less paw swelling, lower arthritis scores, a reduction in bone erosion, less splenomegaly and better maintenance of body weight when compared with nontreated or nontargeted BM-containing liposome groups. Conclusion: Fol-liposomes can selectively deliver imaging and therapeutic agents to sites of inflammation in a rat model of rheumatoid arthritis.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1 . Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin. Arthritis Rheum. 36(3), 182–188 (2006).
- 2 Prevalence of rheumatoid arthritis in low- and middle-income countries: a systematic review and analysis. J. Glob. Health 5(1), 010409 (2015).
- 3 Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 58(1), 15–25 (2008).
- 4 . Rheumatoid arthritis. Lancet 388(10055), 2023–2038 (2016). •• Comprehensive review of pathophysiology, epidemiology, treatment strategies and unmet needs of patients with rheumatoid arthritis (RA).
- 5 Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. Ann. Rheum. Dis. 74(1), 27–34 (2015).
- 6 Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial. Ann. Rheum. Dis. 73(7), 1331–1339 (2014).
- 7 Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomized, controlled trial in new-onset, treatment-naïve, rheumatoid arthritis (the IDEA study). Ann. Rheum. Dis. 73(1), 75–85 (2014).
- 8 Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 52(11), 3381–3390 (2005).
- 9 . Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum. 32(6), 671–676 (1989).
- 10 . Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. J. Rheumaol. 20(11), 1850–1856 (1993).
- 11 . Long-term follow-up of 453 rheumatoid arthritis patients treated with methotrexate: an open, retrospective, observational study. Br. J. Rheumatol. 36(5), 535–540 (1997).
- 12 Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomized controlled trial. Ann. Rheum. Dis. 75(6), 1081–1091 (2016).
- 13 The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54(1), 26–37 (2006).
- 14 Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363(9410), 675–681 (2004).
- 15 . Nanomedicine delivers promising treatments for rheumatoid arthritis. Nanomedicine (Lond.) 10(13), 2063–2074 (2015).
- 16 . Liposomal targeting of glucocorticoids to the inflamed synovium inhibits cartilage matrix destruction during murine antigen-induced arthritis. Int. J. Pharm. 416(2), 486–492 (2011).
- 17 Enhancing methotrexate tolerance with folate tagged liposomes in arthritic mice. J. Biomed. Nanotechnol. 11(12), 2243–2252 (2015).
- 18 Therapeutic effect of methotrexate encapsulated in cationic liposomes (EndoMTX) in comparison to free methotrexate in an antigen-induced arthritis study in vivo. Scand. J. Rheumatol. 44(6), 456–463 (2015).
- 19 Safety of glucocorticoids can be improved by lower yet still effective dosages of liposomal steroid formulations in murine antigen-induced arthritis: comparison of prednisolone with budesonide. Int. J. Pharm. 416(2), 493–498 (2011).
- 20 Nanomedicines for inflammatory arthritis: head-to-head comparison of glucocorticoid-containing polymers, micelles, and liposomes. ACS Nano 8(1), 458–466 (2014).
- 21 . Current trends in the use of liposomes for tumor targeting. Nanomedicine (Lond.) 8(9), 1509–1528 (2013). • Review of targeting liposomes both passively and via ligands to tumors.
- 22 . Folate receptor targeted liposomes encapsulating anti-cancer drugs. Curr. Pharm. Biotechnol. 16(4), 333–343 (2015).
- 23 . Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc. Chem. Res. 41(1), 120–129 (2008).
- 24 . Folate-targeted nanoparticles for rheumatoid arthritis therapy. Nanomedicine 12(4), 1113–1126 (2016). • Comprehensive review of folate-targeted therapies for RA including current delivery systems and future directions for new therapies.
- 25 A folate receptor beta-specific human monoclonal antibody recognizes activated macrophage of rheumatoid patients and mediates antibody-dependent cell-mediated cytotoxicity. Arthritis Res. Ther. 13(2), R59 (2011). •• Development of a folate receptor beta monoclonal antibody and its use to identify FR-β positive activated macrophages from synovial fluid of arthritis patients.
- 26 Synthesis and biological evaluation of EC20: a new folate-derived, (99m)Tc-based radiopharmaceutical. Bioconjug. Chem. 13(6), 1200–1210 (2002).
- 27 . Delivery of liposomes into cultured KB cells via folate-receptor-mediated endocytosis. J. Biol. Chem. 269(5), 3198–3204 (1994).
- 28 . Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo. Bioconjug. Chem. 14(4), 738–474 (2003).
- 29 . Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim. Biophys. Acta 1233(2), 134–144 (1995).
- 30 . Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma. Cancer Lett. 213(2), 165–172 (2004).
- 31 . A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37(8), 911–917 (1959).
- 32 . Two dimensional then layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids 5(5), 494–496 (1970).
- 33 . Tumor-selective radiopharmaceutical targeting via receptor-mediated endocytosis of gallium-67-deferoxamine-folate. J. Nucl. Med. 37(6), 1003–1008 (1996).
- 34 Assessment of three levels of folic acid on serum folate and plasma homocysteine: a randomized placebo-controlled double-blind dietary intervention trial. Eur. J. Clin. Nutr. 56(8), 748–754 (2002).
- 35 Treatment of experimental adjuvant arthritis with a novel folate receptor-targeted folic acid-aminopterin conjugate. Arthritis Res. Ther. 13(2), R56 (2011).
- 36 . A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages. Blood 113(2), 438–446 (2009).
- 37 Folate-targeted imaging of activated macrophages in rats with adjuvant-induced arthritis. Arthritis Rheum. 46(7), 1947–1955 (2002).
- 38 . Folate-targeted immunotherapy effectively treats established adjuvant and collagen-induced arthritis. Arthritis Res. Ther. 8(3), R77 (2006).
- 39 . Folate-targeted hapten immunotherapy of adjuvant-induced arthritis: comparison of hapten potencies. Mol. Pharm. 6(4), 1228–1236 (2009).
- 40 Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies. Bioconjug. Chem. 10(2), 289–298 (1999).
- 41 . Nanotherapeutic approaches for the treatment of rheumatoid arthritis. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 3(6), 607–619 (2011).
- 42 . Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (Lond.) 3(5), 703–717 (2008).
- 43 Therapeutic administration of a selective inhibitor of nitric oxide synthase does not ameliorate the chronic inflammation and tissue damage associated with adjuvant-induced arthritis in rats. J. Pharmacol. Exp. Ther. 284(2), 714–721 (1998).
- 44 . Extra-articular manifestations of rheumatoid arthritis: an update. Autoimmun. Rev. 11(2), 123–131 (2011).
- 45 . Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat. Rev. Rheumatol. 8(11), 656–664 (2012).
- 46 . Liposomes in the treatment of inflammatory disorders. Expert Opin. Drug Deliv. 2(3), 465–476 (2005).
- 47 Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum. 42(8), 1609–1616 (1999). • Expression of folate receptor beta in activated monocytes from RA patients and suggestion of role of FR-β in the transport of methotrexate.
- 48 Effectiveness of anti-folate receptor beta antibody conjugated with truncated pseudomonas exotoxin in the targeting of rheumatoid arthritis synovial macrophages. Arthritis Rheum. 52(9), 2666–2675 (2005).